re: Ann: Collaboration with the MRC Hutchison... The fact is this carried a lot of promise and has turned out to be a commercial nightmare. At this point, it offers no hope of changing anytime soon. That is why they need to do the cap. raising with all its dilution.
It just goes to show that if you want biotech exposure in your portfolio go with something mature, with pipeline breadth and depth and revenues.
Ann: Collaboration with the MRC Hutchison Institu, page-9
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.010(0.72%) |
Mkt cap ! $822.3M | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.41 | $1.35 | $136.6K | 99.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 9461 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 707 | 1 |
View Market Depth
| Last trade - 10.50am 22/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |